Biogen Inc. (BIIB) · Oct 28, 2026 · Earnings
Beat — Non-GAAP EPS $2.62 vs ~$1.99 consensus; revenue $2.804B vs ~$2.63B
Biogen earnings beat on revenue and adjusted EPS as Apellis and rare-disease products accelerate growth, while the 2026 EPS floor rises.
Biogen is in the middle of a deliberate shift away from a shrinking multiple-sclerosis franchise toward a broader growth portfolio built around rare disease, immunology, Alzheimer’s collaboration revenue, and recently acquired Apellis products. The Apellis acquisition added EMPAVELI and SYFOVRE to that growth strategy and was expected to strengthen near-term revenue growth.
| Metric | Q3 2026 | Comparison | Read |
|---|---|---|---|
| Total revenue | $2.804B | $2.535B prior year; ~$2.63B consensus | Beat |
| Non-GAAP diluted EPS | $2.62 | $4.81 prior year; ~$1.99 consensus | Beat |
| GAAP diluted EPS | $(0.14) | $3.17 prior year | Acquisition-heavy quarter |
| Growth Portfolio revenue | $1.26B | Up 49% year over year | Strong expansion |
| Full-year reported Non-GAAP EPS guidance | $12.20–$13.00 | Prior range $12.00–$13.00 | Lower bound raised |
| Free cash flow | $600M | $1.226B prior year | Lower year over year |
The quarter beat the market’s operating expectations. Non-GAAP EPS of $2.62 exceeded published consensus near $2.0, while revenue of $2.804 billion topped the roughly $2.63 billion expectation. The beat was driven by product growth rather than a one-off revenue gain: total product revenue rose 13%, rare-disease revenue rose 27%, specialized-immunology revenue contributed $243 million, and Alzheimer’s collaboration revenue rose 60% (Financial Highlights). The filing says, “Third quarter 2026 total revenue of $2.8 billion increased 11% year-over-year; Growth Portfolio revenue of $1.26 billion, increased 49% year-over-year.”
The growth strategy is now visible in reported sales, but it is not yet a clean earnings story. Spinraza grew 23%, Skyclarys 34%, Zurzuvae 53%, EMPAVELI 92%, and SYFOVRE 27%, while the newly acquired Apellis products supplied a meaningful first full quarter contribution. That momentum more than offset continued pressure in the legacy MS portfolio, where revenue fell 13%, and biosimilars, which declined 16% (Product revenue by franchise). The filing also notes, “Accelerated conversion to high-dose regimen continues to exceed Company expectations across all launched markets” for Spinraza. 〔0〕
The guidance change is modestly better, not a wholesale reset. Biogen raised the bottom of its reported full-year adjusted EPS range from $12.00 to $12.20 while keeping the top at $13.00, citing business strength and less Apellis dilution. That is a positive revision versus the company’s immediately prior outlook, but the filing still embeds roughly $3.20 per share of acquired IPR&D and other upfront or milestone charges plus roughly $0.55 of Apellis dilution (FY 2026 Non-GAAP Diluted EPS Guidance). The company states, “Biogen is raising the lower end of the reported full year 2026 Non-GAAP diluted EPS guidance range to reflect ongoing business strength and Apellis dilution favorability.” 〔1〕
Reported profitability remains weighed down by acquisition and pipeline investment costs. GAAP EPS was a $0.14 loss, and non-GAAP EPS fell 46% year over year despite the revenue beat. The quarter included $284 million of acquired in-process R&D, upfront, and milestone expense, primarily tied to RayThera, alongside higher R&D, SG&A, interest expense, and restructuring charges. The filing says, “Third quarter 2026 GAAP and Non-GAAP diluted EPS include $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc.”
The next test is whether this commercial momentum converts into a durable pipeline-led growth profile. Biogen’s current pipeline strategy centers on late-stage neurology, immunology, and rare-disease programs, with several Phase 3 readouts expected over the next year.
Bottom line: This is a genuine earnings beat and a small guidance improvement, validating the shift toward rare disease and immunology. The business is growing again, but the quarter also shows that acquisition costs, debt-related expense, and declining MS revenue still make the turnaround financially uneven.
TOPAZ-1 and TOPAZ-2 lupus readouts, year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!